Conference Coverage
Multimedia
Don’t miss early joint involvement in psoriasis
WAIKOLOA, HAWAII – Two extra minutes can make a huge difference in improving the early diagnosis.
Conference Coverage
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week...
Conference Coverage
Comorbidities may cut effectiveness of psoriasis biologics
PARIS – In the PSO-BIO-REAL study, PASI 100 rate dropped as the number of comorbidities rose.
Conference Coverage
Brodalumab raced past ustekinumab to PASI 100
PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.
Conference Coverage
Longterm maintenance of PASI 75 responses observed with tildrakizumab
PARIS – More than 90% of PASI 75 responders to tildrakizumab at 6 months maintained at least a PASI 75 response at 148 weeks.
Conference Coverage
CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics
PARIS – Results of the first-ever randomized trial of biologic dose reduction in well-controlled psoriasis patients are reported.
Conference Coverage
Natural killer cells implicated in psoriatic arthritis
CHICAGO – Translational study brings a genetic test for psoriatic arthritis one step closer.
Conference Coverage
Filgotinib shows efficacy, safety in RA phase 3 and PsA phase 2 trials
CHICAGO –
Conference Coverage
Weight loss cuts risk of psoriatic arthritis
CHICAGO – An empowering new message for psoriasis patients.
Conference Coverage
Topical treatments remain a good option for psoriasis
LAS VEGAS – Creams and ointments still have a role, even in the age of biologics.